| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 02.04.
| Synageva BioPharma and Mitsubishi Tanabe Pharma Corporation Expand Development Collaboration with Second Program | | 30 | Business Wire |
| - Additional orphan disease target added to the development program -
Synageva
BioPharma Corp. ("Synageva") (NASDAQ:GEVA), a clinical stage
...
Mehr lesen zu:
Synageva BioPharma and Mitsubishi Tanabe Pharma Corporation Expand Development Collaboration with Second Program | |
| 28.03.
| XFRA DIVIDEND INFORMATION - 28.03.2012 - 11 | | 74 | Xetra Newsboard |
| FOLGENDE WERTPAPIERE WERDEN AM 28.03.2012 EX DIVIDENDE GEHANDELT.
THE EX-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 28.03.2012.
INSTR EXCH ISIN INSTRUMENT NAME DIVIDEND AMOUNT
DKI XFRA JP3481800005...
Mehr lesen zu:
XFRA DIVIDEND INFORMATION - 28.03.2012 - 11 | |
| 27.03.
| Strategic Alliance Between Medicago Inc. and Mitsubishi Tanabe Pharma Corporation Highlighted by Canadian Government in Japan | | 34 | PR Newswire |
| Mitsubishi Tanabe Pharma Identified as Lead Investor in September 2011
Equity Financing
QUEBEC CITY, March 27, 2012 /PRNewswire/ - Medicago Inc. (TSX: MDG), a
biopharmaceutical company focused...
Mehr lesen zu:
Strategic Alliance Between Medicago Inc. and Mitsubishi Tanabe Pharma Corporation Highlighted by Canadian Government in Japan | |
| 27.03.
| XFRA DIVIDEND INFORMATION - 28.03.2012 - 9 | | 44 | Xetra Newsboard |
| FOLGENDE WERTPAPIERE WERDEN AM 27.03.2012 CUM DIVIDENDE UND AM 28.03.2012
EX DIVIDENDE GEHANDELT.
THE PRE-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 27.03.2012. THE
EX-DIVIDEND DAY WILL BE 28.03.2012.
...
Mehr lesen zu:
XFRA DIVIDEND INFORMATION - 28.03.2012 - 9 | |
| 06.03.
| Medicago Inc. and Mitsubishi Tanabe Pharma Corporation Enter into a Strategic Alliance to Develop New Vaccines | | 6 | PR Newswire |
| Medicago to Receive up to $33 Million in Upfront and Milestone Payments
as well as Royalties under a First Agreement to Develop a Rotavirus
Vaccine
QUEBEC CITY, March 6, 2012 /PRNewswire/ - Medicago...
Mehr lesen zu:
Medicago Inc. and Mitsubishi Tanabe Pharma Corporation Enter into a Strategic Alliance to Develop New Vaccines | |
| 28.02.
| For the Treatment of Crohn's Disease, Current and Emerging Therapies Have No Advantage in the Induction of Remission over Janssen Biotech/Merck/Mitsubishi Tanabe's Remicade | | 23 | Business Wire |
| The Crohn's Disease Drug Market Will Increase from Approximately
$3.3 Billion in 2010 to $4.5 Billion in 2020, According to Findings from
Decision Resources
...
Mehr lesen zu:
For the Treatment of Crohn's Disease, Current and Emerging Therapies Have No Advantage in the Induction of Remission over Janssen Biotech/Merck/Mitsubishi Tanabe's Remicade | |
| 13.01.
| Nuron Biotech Licenses HibTITER® Vaccine to Mitsubishi Tanabe Pharma Corporation for Japanese Market | | 36 | Business Wire |
| Nuron
Biotech Inc., a specialty biologics and vaccines company, today
announced that it has licensed its HibTITER® vaccine to Mitsubishi
Tanabe Pharma Corporation...
Mehr lesen zu:
Nuron Biotech Licenses HibTITER® Vaccine to Mitsubishi Tanabe Pharma Corporation for Japanese Market | |
